Top 10 Tech Stocks To Own Right Now

The holy grail of drug development is launching a billion-dollar blockbuster therapy, but that isn't easy to do. It costs more than $1 billion to usher compounds through expensive clinical trials (including failures) and just 10% of drugs in pipelines ever make it to market.

The hit-and-miss nature of the industry suggests that only the most sophisticated (and risk-taking) investors should buy biotechnology stocks, but for those who invest in the space there are few things as profit-friendly as catching a billion-dollar blockbuster in the making.

That leads me to Medivation (NASDAQ: MDVN  ) , Ophthotech (NASDAQ: OPHT  ) , and Portola (NASDAQ: PTLA  ) , three companies with important therapies that may very well be destined to become top sellers.

MDVN data by YCharts.

Source: Medivation

Hot Casino Stocks To Buy For 2015: Perceptron Inc.(PRCP)

Perceptron, Inc. develops, produces, and sells non-contact measurement and inspection solutions in the Americas, Europe, and Asia. It offers AutoGauge systems that are used in the assembly and fabrication plants of automotive manufacturers; AutoGauge Plus, which offers freeform surface scanning and discrete feature measurement in one solution; AutoFit systems that are used in automotive manufacturing plants to contain, correct, and control the fit of exterior body panels; AutoScan systems, which provide a non-contact method of gathering data for the analysis of the surface contour of a part or product; and AutoGuide systems to calculate the difference between theoretical and actual relationships of a robot and the part being assembled, and send compensation data in six degrees of freedom to the robot. The company also offers ScanWorks, a hardware/software component set that allows customers to add digitizing capabilities to their machines or systems; ScanWorks xyz, a 3D sc anning solution designed for retrofitting 3-axis machines; ToolKit, a software solution for CMM manufacturers, system integrators, and application software developers; WheelWorks software and sensors that offer a non-contact method of measuring wheel position for use in automated or manual wheel alignment machines in automotive assembly plants; and Multi-line Sensors for use in automotive assembly plant wheel alignment systems. In addition, it manufactures visual inspection devices and accessories for the mechanical market; plumbing diagnostic equipment, meter imager systems, line detector accessories, and handheld inspection devices for the plumbing market; optical inspection devices for the construction and DIY market; and imaging solutions for the electrical market, as well as offers value-added services, including training, field services, launch support, consulting, maintenance agreements, repairs, and software tools. The company was founded in 1981 and is headquartered in Plymouth, Michigan.

Advisors' Opinion:

• [By Garrett Cook]

  In trading on Tuesday, industrials shares were relative leaders, up on the day by about 0.26 percent. Top gainers in the sector included Perceptron (NASDAQ: PRCP), up 10.9 percent, China Ming Yang Wind Power Group (NYSE: MY), up 4.8 percent.

Top 10 Tech Stocks To Own Right Now: Imagination Technologies Group PLC (IGNMF.PK)

Imagination Technologies Group plc is engaged in multimedia and communication technologies. The Company operates in two segments: Technology business and the Pure business. The Company�� Technology business segment is engaged in the development of embedded graphics, video, display and multi-threaded processor and multi-standard broadcast receiver and connectivity technologies for licensing to semiconductor companies for incorporation into silicon devices. The Company�� Pure business segment is engaged in the development and marketing of consumer products to showcase the technologies of the Technology business and to develop markets for such technologies. In March 2012, Toumaz Ltd completed the exchange of Imagination Technologies Group plc's interest in Toumaz Ltd�� Toumaz Microsystems subsidiary. In February 2013, it acquired the operating business and certain patent properties of MIPS Technologies, Inc. Advisors' Opinion:

• [By Ashraf Eassa]

  However, I expect that Intel is at risk of having a significant marketing problem trying to sell a dual core product into a world of quad core phones, even if the dual core part delivers better performance/watt. I further expect that from what is currently known about Bay Trail's GPU (4 EU Gen7 GPU), it is unlikely that -- unless Intel is either using Imagination's (IGNMF.PK) next generation PowerVR 6 or a beefed up Gen7 design for the "Merrifield" SoC -- it will be as competitive with the Snapdragon 800 on the GPU side of things, which could pose as an additional headwind to adoption. I also believe that the Q1 2014 launch curtails any hope that there will be a 14nm smartphone product launched in 2014 (although Mr. Krzanich's comments about "acceleration" could be a source of optimism here), which means that the company's process lead could ultimately prove to be ephemeral in this particular end market. Fortunately, product cycles in this space are short, so it may be okay to have Merrifield be reasonably short lived.

Top 10 Tech Stocks To Own Right Now: Convergys Corporation (CVG)

Convergys Corporation provides relationship management solutions in North America and internationally. Its Customer Management segment offers agent-assisted, self-service, and intelligent technology care solutions, including customer service, customer retention, sales, technical support, social interaction, collections management, back office, business-to-business, customer experience applied analytics, and intelligent interaction solutions for communications, financial services, technology, retail, healthcare, and government markets. This segment also provides premise-based and hosted automated self-care and technology solutions; speech recognition solutions; and license, professional, consulting and maintenance, and software support services. Convergys Corporation was founded in 1998 and is headquartered in Cincinnati, Ohio.

Advisors' Opinion:

• [By Jake L'Ecuyer]

  Convergys (NYSE: CVG) was also up, gaining 12.44 percent to $23.46 after the company announced its plans to acquire Stream Global Services for $820 million in cash. Convergys also reaffirmed its outlook for 2013.

Top 10 Tech Stocks To Own Right Now: Model N Inc (MODN)

Model N, Inc., incorporated on December 14, 1999, is a provider of revenue management solutions for the life science and technology industries. The Company�� solutions enable its customers to maximize revenues and reduce revenue compliance risk by transforming their revenue lifecycle from a series of tactical, disjointed operations into a strategic end-to-end process. The Company�� customers use its application suites to manage mission-critical functions, such as pricing, contracting, incentives and rebates. Its solutions include two complementary suites of software applications, Revenue Management Enterprise and Revenue Management Intelligence. On January 18, 2012, the Company acquired certain assets of LeapFrogRx, Inc. (LeapFrogRx), a privately held cloud-based analytics solution provider for the pharmaceutical industry.

The Company provides solutions that span the organizational and operational boundaries of functions such as sales, marketing and finance, and serve as a system of record for key revenue management processes including pricing, contracts, rebates and regulatory compliance. Its application suites are purpose-built for the life science and technology industries and are designed to work with enterprise resource planning (ERP) and customer relationship management (CRM) applications that do not typically provide revenue management capabilities by enabling real-time pricing, managing contracts and automating channel incentives management, including rebates.

Revenue Management Enterprise suite

A broad set of transactional applications that serve as a system of record for, and automate the execution of revenue management processes such as incentive and rebate management, pricing and contracting. This suite includes its Price Management, Deal Management, Contract Management, Incentive and Rebate Management and Regulatory Compliance Management applications, which can be purchased together as a suite or as separate stand-alone applications.

Revenue Management Intelligence suite

A broad set of intelligence applications that provide the analytical insights to define and optimize revenue management strategies. This suite includes its Price Strategy, Brand Strategy, Channel Strategy, Managed Markets Strategy and International Reference Pricing applications, which can be purchased together as a suite or as separate stand-alone applications.

Advisors' Opinion:

• [By Rick Munarriz]

  I went out on a limb last week, and now it's time to see how that decision played out.

  I predicted that Model N (NYSE: MODN  ) would post a smaller loss than analysts were expecting. The provider of revenue management solutions has been a dud since going public nearly a year ago, but one thing it has consistently done is post a smaller deficit than what the pros are forecasting. Wall Street was settling for a loss of $0.12 a share, and Model N sported only $0.03 a share in red ink. The stock soared 19% on Tuesday after the better-than-expected report. I was right. After more than a year of predicting that the tech-heavy Nasdaq would outperform the Dow Jones Industrial Average � (DJINDICES: ^DJI  ) , I mixed things up two weeks ago. I simply predicted that the Dow would bounce back after plunging 3.5% and 1.1% over the prior two weeks. I repeated the call this time around, and the Dow responded with a hearty 2.3% gain. I was right.� My final call was for LeapFrog (NYSE: LF  ) to beat Wall Street's income estimates in its latest quarter. The maker of electronic learning toys has been routinely beating Wall Street projections over the past year. I was banking on a repeat performance, but it wasn't to be. LeapFrog merely broke even on a sharper drop in revenue than expected. Analysts had been braced for a profit of $0.14 a share. I was wrong.

  Two out of three? I can do better than that. Let me once again whip out my trusty, dusty, and occasionally accurate crystal ball to make three calls that may play out over the next few trading days.

• [By Lee Jackson]

  Model N Inc. (NYSE: MODN) develops applications, such as managed care and government pricing, for life science companies and channel incentives based on design wins for technology companies. The company’s customers use its application suites to manage mission-critical functions, such as pricing, contracting, incentives and rebates. The company had a recent initial public offering (IPO) that traded as high as $24.80 before badly missing earnings and being taken to the woodshed. Deutsche Bank still rates it as a stock to buy and has a $12 price target. The consensus target is at $15. The stock closed Friday at $9.88.

Top 10 Tech Stocks To Own Right Now: Durata Therapeutics Inc (DRTX)

Durata Therapeutics, Inc., incorporated on November 4, 2009, is a pharmaceutical company focused on the development and commercialization of therapeutics for patients with infectious diseases and acute illnesses. The Company enroll and dose patients in two global Phase III clinical trials with its product candidate, dalbavancin, for the treatment of patients with acute bacterial skin and skin structure infections (abSSSI). Dalbavancin is an intravenous antibiotic product candidate designed for once-weekly dosing. In addition to abSSSI, the Company focuses on the development of dalbavancin for additional indications, including osteomyelitis, diabetic foot infection and pneumonia.

As of December 31, 2011, Dalbavancin had already completed three Phase III clinical trials, in which more than 1,000 patients in total received dalbavancin. Dalbavancin achieved its primary efficacy endpoint of non-inferiority in each of these three completed Phase III clinical trials when compared to linezolid, cefazolin or vancomycin, three of the standard-of-care agents for uncomplicated skin and skin structure infections (uSSSI), and complicated skin and skin structure infections (cSSSI). Its two ongoing Phase III clinical trials are designed to compare dalbavancin to vancomycin, with an option to switch to oral linezolid, under the new FDA draft guidance.

The Company competes with Pfizer, Cubist Pharmaceuticals, Inc., Theravance, Inc., Forest Laboratories, Inc., Sanofi-Aventis Ltd., The Medicines Company, Trius Therapeutics, Inc., Cempra, Inc., Rib-X Pharmaceuticals, Inc., Paratek Pharmaceuticals, Inc., Nabriva Therapeutics AG, Tetraphase Pharmaceuticals, Inc. and Furiex Pharmaceuticals, Inc.

Advisors' Opinion:

• [By Lisa Levin]

  Durata Therapeutics (NASDAQ: DRTX) shares climbed 5.30% to $14.18. The volume of Durata Therapeutics shares traded was 861% higher than normal. The FDA Advisory Committee unanimously recommended the approval of Durata's Dalvance.

Top 10 Tech Stocks To Own Right Now: Vmware Inc.(VMW)

VMware, Inc. provides virtualization and virtualization-based cloud infrastructure solutions in the United States and internationally. The company?s products address planned and unplanned downtime management, system recoverability and reliability, backup and recovery, resource provisioning and management, capacity and performance management, and security issues. Its cloud infrastructure products and technologies include VMware vSphere, which is a data center platform that also enables live migration of actively running virtual machines across servers or storage locations without disruption or downtime; enables availability for all applications against hardware and operating system failures; and enables centralized point of control for cluster-level networking, as well as automatically manages the placement and balancing of a virtual machine across storage resources. The company also offers cloud application platform solutions that help organizations build, run, and manage enterprise applications in public, private, or hybrid clouds optimized for vSphere. In addition, it provides end-user computing solutions, which provide secure access to applications and data from various devices and location, as well as serves the corporate IT departments through managing and connecting end-user assets delivering them as a managed service. The company?s end-user computing solutions also provide the ability to manage software as a service, Windows, Mobile, or enterprise applications, as well as enhance communication and collaboration between end users. Further, it provides a range of professional services, such as consulting, education, and technical account manager services, as well as customer support services. The company sells its products through distributors, resellers, system vendors, and systems integrators. VMware, Inc. was incorporated in 1998 and is headquartered in Palo Alto, California. VMware, Inc. operates as a subsidiary of EMC Corporation.

Advisors' Opinion:

• [By James O'Toole]

  The Palo Alto, Calif., based company was founded in 2012 by security experts formerly of Google (GOOG) and VMware (VMW). Joe Sullivan, Facebook's chief security officer, said PrivateCore's technology "protects servers from persistent malware, unauthorized physical access, and malicious hardware devices."

Top 10 Tech Stocks To Own Right Now: Conatus Pharmaceuticals Inc (CNAT)

Conatus Pharmaceuticals Inc., incorporated on July 13, 2005, is a biotechnology company focused on the development and commercialization of medicines to treat liver disease. The Company is developing its lead compound, emricasan, for the treatment of patients in orphan populations with chronic liver disease and acute exacerbations of chronic liver disease. The Company has designed a clinical program to demonstrate the therapeutic benefit of emricasan across the spectrum of fibrotic liver disease. The Company�� initial development strategy targets indications for emricasan with high unmet clinical need in orphan patient populations, such as patients with acute-on-chronic liver failure (ACLF), chronic liver failure (CLF), and patients who have developed liver fibrosis post-orthotopic liver transplant due to Hepatitis C virus infection (HCV-POLT).

The Company has completed two placebo-controlled Phase II trials in patients with liver disease showing reductions in ALT levels that occur rapidly, within as little as one day after initiation of therapy, and are maintained throughout the treatment period. In the Company�� 204-patient Phase 2b trial, it also measured cCK18, an important biomarker of apoptosis and disease severity. Emricasan has been generally well-tolerated in all of the clinical studies. As of July 23, 2013, the Company had not generated any revenue.

Advisors' Opinion:

• [By John Udovich]

  While Intercept Pharmaceuticals Inc (NASDAQ: ICPT) surged earlier this year and Achillion Pharmaceuticals, Inc (NASDAQ: ACHN) has surged this week after Merck & Co. Inc (NYSE: MRK) agreed to purchase hepatitis stock�Idenix Pharmaceuticals Inc (NASDAQ: IDIX) at a 239% premium, it seems the herd has realized that small cap Conatus Pharmaceuticals Inc (NASDAQ: CNAT) is also a liver disease stock as shares suddenly surged 56.69% on no apparent company news. But just what is�Conatus Pharmaceuticals and is it worth taking a chance on?